Hib-DTP-hepatitis B vaccine - Heber Biotec/Center for Genetic Engineering and Biotechnology

Drug Profile

Hib-DTP-hepatitis B vaccine - Heber Biotec/Center for Genetic Engineering and Biotechnology

Alternative Names: Heberpenta 4+1; Heberpenta-L

Latest Information Update: 17 Dec 2013

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Haemophilus vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus

Most Recent Events

  • 01 Dec 2013 Launched for Diphtheria, Haemophilus infections, Pertussis, Tetanus and Hepatitis B (prevention in infants and children) in Argentina, Ecuador, Uruguay and Venezuela before December 2013 (IM)
  • 01 Dec 2010 Launched for Diphtheria, Tetanus, Pertussis, Haemophilus infections and Hepatitis B (prevention in infants and children) in Cuba (IM; liquid premixed)
  • 10 Nov 2009 Phase-II clinical trials in Diphtheria, Tetanus, Pertussis, Haemophilus infections and Hepatitis B (prevention in infants and children) in Cuba (IM; liquid premixed)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top